Vaccines for Cancer Immunotherapy: A Comprehensive Evidence-based Review on Current Status and Future Perspectives not only provides a reference on cancer treatment for clinicians, but also presents a well-organized resource for determining high-potential research areas. The book considers that this promising modality can be made more feasible as a treatment for cancer. Chapters cover cancer immunology, general approaches to cancer immunotherapy, vaccines, tumor antigens, the strategy of allogeneic and autologous cancer vaccines, personalized vaccines, whole tumor antigen vaccines, protein and peptide vaccines, dendritic cell vaccines, genetic vaccines, candidate cancers for vaccination, future perspectives on therapeutic cancer vaccines, and more.
- Introduces the feasible immunotherapeutic vaccines for patients with different cancer types
- Presents the status of past and current vaccines for cancer treatment
- Considers the advantages and disadvantages of therapeutic cancer vaccines in comparison to conventional treatments
- Looks at the combination of vaccines and other modalities, including immunotherapeutic and conventional methods
- Analyzes obstacles in the development of therapeutic cancer vaccines
- Gives a view on future perspectives towards the application of therapeutic cancer vaccines
1. Cancer immunology 2. General approaches in cancer immunotherapy 3. Vaccines 4. Tumor antigens 5. The Strategy of Allogeneic and Autologous Cancer Vaccine 6. Personalized Vaccine 7. Whole Tumor Antigen Vaccine 8. Protein and Peptide vaccines 9. Dendritic Cell vaccine 10. Genetic Vaccine 11. Candidate cancers for vaccination 12. The obstacles in development of Therapeutic Cancer Vaccine 13. Combination Therapy 14. The Future Perspective for Therapeutic Cancer Vaccine 15. Concluding remarks on Therapeutic Cancer Vaccine 16. References
Nima Rezaei is Associate Professor of Clinical Immunology at Tehran University of Medical Sciences, Associate Dean of International Affairs in the School of Medicine, and Director of the Global Academic Program. He received his PhD in clinical immunology and human genetics from the University of Sheffield in the UK. He edits and writes for leading book series, and is the founder and advisor of two research interest groups, the Network of Immunity in Infection, Malignancy and Autoimmunity (NIMA) and the Cancer Immunology Project (CIP).
Mahsa Keshavarz-Farthi is a medical researcher at the Tehran University of Medical Sciences, and the managing director of Cancer Immunology Project (CIP), undertaking and managing different research project in the field of cancer immunology and immunotherapy. She is working on several research projects on immunotherapeutic modalities for cancer.